International Journal of Nephrology

International Journal of Nephrology is an open-access medical journal devoted to the prevention, diagnosis and management of kidney disease and of the disorders that accompany it.《国际肾脏病学杂志》是一本开放获取的医学期刊，专注于肾脏疾病及其伴随病症的预防、诊断与管理。

Publication began with a volume dated 2010, and the title has come out without a break since, one volume for each calendar year and accepted papers folded into the volume of their year.该刊自 2010 年的一卷起步，此后未曾中断，每个日历年编成一卷，录用的论文归入当年那一卷。

Original research, review articles and clinical studies account for most of what it prints, and the balance leans toward practice at the bedside rather than toward laboratory work alone.原创研究、综述与临床研究构成刊物的主体，重心偏向病床边的实践，而不止于实验室工作。

Coverage reaches hypertension, dialysis, transplantation and the metabolic disturbances that follow loss of renal function, so general physicians find material here as well as subspecialists.选题涵盖高血压、透析、移植，以及肾功能丧失后的代谢紊乱，普通内科医师与专科医师都能在此找到可用的材料。

Every article is free to read on the day it appears, and the licence allows reuse provided the source is credited, so the whole archive stays open from the first volume onward.每篇文章在刊出当日即可免费阅读，许可条款允许在注明出处的前提下重复使用，自首卷起的全部档案保持开放。

The readership is made up chiefly of nephrologists, transplant physicians, dialysis unit staff and clinical researchers who need findings that transfer to routine care.读者主要为肾内科医师、移植科医师、透析中心人员与临床研究者，他们需要能够转入日常诊疗的发现。

Scope

• The stated aim is work on the prevention, diagnosis and management of kidney disease and related diseases, and that clinical frame governs how submissions are screened.刊物申明的宗旨是刊载肾脏疾病及相关疾病的预防、诊断与管理研究，这一临床框架决定了稿件的初筛口径。

• Chronic kidney disease is a standing subject, taking in epidemiology, risk prediction, the course of progression and the preparation of patients for renal replacement therapy.慢性肾脏病是常设题目，涉及流行病学、风险预测、进展过程，以及患者进入肾脏替代治疗前的准备。

• Acute kidney injury is treated with the same seriousness, including its recognition in hospital practice and the sequelae that outlast the acute episode.急性肾损伤受到同等重视，包括住院实践中的识别，以及急性期过后仍然持续的后遗问题。

• Dialysis appears in both of its main forms, so papers on vascular access, on the adequacy of haemodialysis and on its complications sit beside work on peritoneal dialysis.透析的两种主要形式都在其中，血管通路、血液透析充分性与并发症方面的论文，与腹膜透析方面的研究并列刊出。

• Transplantation has a section to itself, covering donor assessment, immunosuppressive regimens, rejection and the long-term function of the graft.移植自成一类，涵盖供者评估、免疫抑制方案、排斥反应与移植物的长期功能。

• Glomerular disease is admitted, and reports on nephrotic and nephritic syndromes, on IgA nephropathy and on lupus nephritis turn up among the clinical papers.肾小球疾病在收稿之列，肾病综合征与肾炎综合征的报告，以及 IgA 肾病与狼疮性肾炎的研究，出现在临床论文之中。

• Diabetic kidney disease and the renal damage wrought by hypertension draw steady submissions, since both are leading roads to end-stage renal failure across the world.糖尿病肾病与高血压造成的肾脏损害持续吸引投稿，两者在全世界都是通往终末期肾衰竭的主要路径。

• Electrolyte and acid-base disorders, together with the bone and mineral disturbances of chronic kidney disease, are handled as clinical problems and not as physiology for its own sake.电解质与酸碱失衡，连同慢性肾脏病中的骨与矿物质代谢紊乱，被当作临床问题处理，而非单纯的生理学议题。

• Paediatric nephrology has a place, with papers on congenital anomalies, on childhood hypertension and on the passage of young patients into adult services.儿童肾脏病占有一席之地，先天性异常、儿童期高血压，以及年轻患者转入成人医疗的论文都在其中。

• Health services research falls inside the remit, particularly studies of how dialysis care is organised and of access to treatment where resources are scarce.卫生服务研究属于收稿范围，尤其是透析照护如何组织，以及资源匮乏地区获得治疗的机会方面的研究。

• Reviews come both by commission and on offer, and a review is meant to map a field for the clinician instead of rehearsing the literature paper by paper.综述既有约稿也有自由来稿，一篇综述应当为临床医师勾画领域轮廓，而不是逐篇复述文献。

• Case reports appear from time to time, usually when the observation carries a lesson beyond the single patient described.病例报告时有出现，通常见于所观察到的现象能带来超出单一患者之教益的情形。

History

• The journal was founded in 2010 under the SAGE-Hindawi Access to Research imprint, a London-based open-access operation that SAGE and Hindawi ran together.该刊于 2010 年创刊，出版方为 SAGE-Hindawi Access to Research，这一伦敦的开放获取出版机构由 SAGE 与 Hindawi 共同经营。

• That first volume carried the year itself as its number, and the practice has held, so a paper from 2015 sits in volume 2015 and not in a running count of volumes.首卷直接以年份作为卷号，这一做法沿用至今，2015 年的论文归入 2015 年卷，而不按连续卷次计数。

• Ownership then passed to Hindawi Publishing Corporation, whose name still appears in the publisher field of the journal-level Crossref record for the title.此后刊物归属 Hindawi Publishing Corporation，直到今天该刊在 Crossref 刊级记录中的出版方字段仍写着这家公司。

• Wiley bought Hindawi in 2021, and the deal carried a portfolio of open-access titles, this one among them, into a larger commercial publisher.Wiley 于 2021 年收购 Hindawi，这笔交易把一批开放获取刊物并入规模更大的商业出版机构，本刊即在其列。

• Deposits from 2022 onward name Wiley as publisher, and the National Library of Medicine has given the current imprint as Hoboken, New Jersey since 2023.2022 年起的送存记录以 Wiley 为出版方，美国国家医学图书馆自 2023 年起把现行出版地记为新泽西州霍博肯。

• Wiley announced at the end of 2023 that the Hindawi name would be retired, and the former Hindawi titles were regrouped into the Wiley Forward series during 2024, which is how the journal now describes its own publishing arrangement.Wiley 于 2023 年末宣布停用 Hindawi 这一名称，原属 Hindawi 的各刊在 2024 年间重组进 Wiley Forward 系列，本刊如今也以该系列说明自身的出版安排。

• Open access has been the model from the outset, and the 2025 Journal Citation Reports credit the journal with a gold open-access share of 100 per cent.开放获取自创刊起便是既定模式，2025 年版期刊引证报告给出的金色开放获取比例为 100%。

• Authors pay an article processing charge, put by the Directory of Open Access Journals at 1,100 United States dollars, and no subscription barrier stands in front of the text.作者需支付文章处理费，开放获取期刊目录记录的数额为 1,100 美元，正文之前不设订阅门槛。

• PubMed and PubMed Central have carried the journal since the first volume, and it is indexed in the Emerging Sources Citation Index rather than in the Science Citation Index Expanded.PubMed 与 PubMed Central 自首卷起收录该刊，其索引位置在新兴来源引证索引，未进入科学引证索引扩展版。

• The impact factor stood at 1.7 in the 2023 edition, fell to 1.4 in 2024 and returned to 1.9 in 2025, with a five-year figure of 2.3.影响因子在 2023 年版为 1.7，2024 年降至 1.4，2025 年回到 1.9，五年影响因子为 2.3。

• Its place in Urology and Nephrology is the third quartile, at 81 of 134 titles in the 2025 listing, and the journal citation indicator reads 0.47.该刊在泌尿与肾脏病学类目处于第三区，2025 年榜单列 134 种刊物的第 81 位，期刊引证指标为 0.47。

• Output has stayed modest, at roughly 23 articles in the 2025 census, and from 2024 each annual volume has been closed as a single numbered issue.发文量一直不大，2025 年统计约为 23 篇，自 2024 年起每一卷以单独一个编号期次结卷。

Editors

• Handling rests with academic editors, and every manuscript that enters review is assigned to one of them, who obtains the reports and recommends a decision to the editor in charge.稿件处理由学术编辑承担，凡进入评审的稿件都会指派给其中一位，由其取得审稿报告并向主管编辑提出处理建议。

• Review is single anonymous, as the Directory of Open Access Journals records it, so a referee sees the authors' names while the authors never learn who reported on them.评审采取单盲方式，开放获取期刊目录即如此记载，审稿人能看到作者姓名，作者则始终不知报告出自何人。

• The editorial board page on the publisher's site sets out the academic editors with their institutions, which lets a prospective author see who is likely to take a given subject.出版方网站上的编委页面列出学术编辑及其所在机构，投稿人由此可以看出某一题材可能由谁经手。

• Editorial expertise is spread across clinical nephrology, from dialysis and transplantation to glomerular disease and the care of patients with diabetic kidney disease.编辑专长分布在临床肾脏病的各个方向，从透析与移植，到肾小球疾病，再到糖尿病肾病患者的照护。

• Authors submit through the publisher's online system, and the declarations on ethics approval, on patient consent and on competing interests travel with the manuscript from the start.作者经出版方的在线系统投稿，伦理批准、患者知情同意与利益冲突方面的声明自投稿起随稿提交。

• Reviews and clinical studies pass through peer review on the same footing as original research, since the scope statement treats all three as research contributions.综述与临床研究与原创研究在同一基础上接受同行评审，刊物的宗旨把这三类都视为研究性稿件。

• Decisions rest on the reports, and a revised manuscript usually goes back to the editor who handled it the first time, which keeps one line of responsibility through the rounds.决定以审稿报告为依据，修回稿通常回到最初经手的那位编辑，责任线索由此贯穿各轮修改。

• Editorial business runs through the publisher's office, since no learned society stands behind the title and no separate secretariat handles correspondence.编辑事务由出版方的编辑部办理，该刊没有学会主办，也没有单独的秘书处处理往来函件。

• Articles appear under a licence that permits reuse with attribution, and the editorial file, the identities of referees included, stays closed once the paper is out.文章以允许署名复用的许可发布，论文刊出之后编辑档案仍不公开，其中包括审稿人的身份。